From: Effects of early corticosteroid use in patients with severe coronavirus disease 2019
 | Early use group (n = 12) | Late use group (n = 10) | p-value |
---|---|---|---|
Combination therapy | |||
 Steroid | 7/12 (58.3%) | 8/10 (80.0%) | 0.162 |
 Steroid + Convalescent plasma | 5/12 (41.7%) | 1/10 (10.0%) | |
 Steroid + Remdesivir | 0 | 1/10 (10.0%) | |
Steroid-related factor | |||
 Time from symptom to steroid use | 9.75 ± 3.64 | 15.70 ± 6.00 | 0.010 |
 Time from diagnosis to steroid use | 3.00 (2.00–7.00) | 12.5 (11.00–14.25) | < 0.001 |
 Time from hospitalization to steroid use | 3.33 ± 3.45 | 10.00 ± 4.83 | 0.001 |
 Initial dosea, mg/kg/day | 0.81 (0.50–1.00) | 1.00 (0.76–.1.00) | 0.456 |
 Duration, days | 14.00 ± 5.00 | 18.50 ± 14.76 | 0.380 |
 Total dosea, mg | 521.6 ± 246.38 | 667.50 ± 606.76 | 0.490 |
Score on ordinal scale at steroid start | Â | Â | 0.035 |
 O2 with nasal prong | 1/8 (12.5%) | 0 |  |
 High flow nasal cannula | 7/8 (87.5%) | 2/5 (40%) | |
 Invasive ventilation | 0 | 3/5 (60%) |